Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism

European Journal of Endocrinology

Volumn 141, Issue 3, 1999, Pages 195-210

  Hofbauer, Lorenz C ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; LIGAND;

ALBERS SCHOENBERG DISEASE; BONE METABOLISM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HORMONAL REGULATION; METABOLIC BONE DISEASE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE REMODELING; CARRIER PROTEINS; CYTOKINES; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLYCOPROTEINS; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOCLASTS; OSTEOPETROSIS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RATS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0032855826     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410195     Document Type: Review

References (88)

1. Suda T, Takahashi N & Martin TJ. Modulation of osteoclast differentiation. Endocrine Reviews 1992 13 66-80.
2. Suda T, Nakamura I, Jimi E & Takahashi N. Regulation of osteoclast function. Journal of Bone and Mineral Research 1997 12 869-879.
3. Roodman GR. Advances in bone biology: the osteoclast. Endocrine Reviews 1996 17 308-332.
4. Reddy SV & Roodman GD. Control of osteoclast differentiaton. Critical Reviews in Eukaryotic Gene Expression 1998 8 1-17.
5. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. Journal of Bone and Mineral Research 1996 11 1043-1051.
6. Manolagas SC & Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. New England Journal of Medicine 1995 332 305-311.
7. Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone 1998 23 75-81.
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309-319.
9. Yasuda H, Shima N, Nakagawa N, Mochizuki S-I, Yano K, Fujise N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 139 1329-1337.
10. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 165-176.
11. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the USA 1998 95 3597-3602.
12. Orlinick JR & Chao MV. TNF-related ligands and their receptors. Cellular Signalling 1998 10 543-551.
13. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997 204 35-46.
14. Kwon BS, Wang S, Udagawa N, Haridas V, Lee ZH, Kim KK et al. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB Journal 1998 12 845-854.
15. Tsuda E, Goto M, Mochizuki S-I, Yano K, Kobayashi F, Morinaga T et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications 1997 234 137-142.
16. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. Journal of Immunology 1998 161 6113-6121.
17. Tomoyasu A, Goto M, Fujise N, Mochizuki S, Yasuda H. Morinaga T et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochemical and Biophysical Research Communications 1998 245 382-387.
18. Yamaguchi K, Kinosaki M, Goto M, Koboyashi F, Tsuda E, Morinaga T et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. Journal of Biological Chemistry 1998 273 5117-5123.
19. Morinaga T, Nakagawa N, Yasuda H, Tsuda E & Higashio K. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. European Journal of Biochemistry 1998 254 685-691.
20. Mizuno A, Murakami A, Nakagawa N, Yasuda H, Tsuda E, Morinaga T et al. Structure of the mouse osteoclastogenesis inhibitory factor/osteoprotegerin gene and its expression in embryogenesis. Gene 1998 215 339-343.
21. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL & Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochemical and Biophysical Research Communications 1998 250 776-781.
22. Vidal NOA, Brändström H, Jonsson KB & Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. Journal of Endocrinology 1998 159 191-195.
23. Hofbauer LC, Gori F, Riggs BL, Dunstan CR, Lacey DL, Spelsberg TC & Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999 (In Press).
24. Hofbauer LC, Khosla S, Dunstan CR, Spelsberg TC & Riggs BL. Estrogen stimulates production of the anti-resorptive cytokine receptor osteoprotegerin in human osteoblastic cells. Endocrinology 1999 (In Press).
25. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 1260-1268.
26. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemical and Biophysical Research Communications 1998 247 610-615.
27. Miyamoto A, Kunisada T, Hemmi H, Yamane T, Yasuda H, Miyake K et al. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochemical and Biophysical Research Communications 1998 242 703-709.
28. Emery JG, McDonnell P, Brigham Burke M, Deen KC, Lyn S, Silverman C et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry 1998 273 14363-14367.
29. Tan H-L, Van G, Scully S, Shimamoto G, Kelley M, Boyle B et al. Recombinant osteoprotegerin (OPG), a novel TNF-receptor family member, inhibits in vitro murine osteoclast formation from bone marrow precursors. Journal of Bone and Mineral Research 1997 12 (Suppl 1) S155 (Abstract no. P213).
30. 2, or parathyroid hormone in the microenvironment of bone. Biochemical and Biophysical Research Communications 1998 246 337-341.
31. Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochemical and Biophysical Research Communications 1998 251 796-801.
32. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E et al. Osteoclastogenesis-inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochemical and Biophysical Research Communications 1998 250 229-234.
33. Fuller K, Wong B, Fox S, Choi Y & Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. Journal of Experimental Medicine 1998 188 997-1001.
34. Dunstan CR, Capparelli C, Kelley M, Shimamoto G, Kaufman S, Russell D et al. Osteoprotegerin (OPG), a novel TNF-receptor family member, profoundly inhibits endosteal bone resorption due to growth, humoral hypercalcemia of malignancy, and interleukin 1. Journal of Bone and Mineral Research 1997 12 (Suppl 1) S136 (Abstract no. 134).
35. Yamamoto M, Murakami T, Nishikawa M, Tsuda E, Mochizuki S-I, Higashio K et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998 139 4012-4015.
36. Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki S-I et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998 23 495-498.
37. Vidal ONA, Sjögren K, Eriksson BI, Ljunggren Ö & Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochemical and Biophysical Research Communications 1998 248 696-700.
38. Brändström H, Jonsson KB, Vidal O, Ljunghall, Ohlsson C & Ljunggren Ö. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochemical and Biophysical Research Communications 1998 248 454-457.
39. Horwood NJ, Elliott J, Martin TJ & Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998 139 4743-4746.
40. Murakami T, Yamamoto M, Yamamoto M, Ono K, Nishikawa M, Nagata N et al. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochemical and Biophysical Research Communications 1998 252 747-752.
41. Spinas GA, Keller U & Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. Journal of Clinical Investigation 1992 90 533-536.
42. Chenu C, Pfeilschifter J, Mundy GR & Roodman GD. Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proceedings of the National Academy of Sciences of the USA 1988 85 5683-5687.
43. Pfeilschifter J, Seyedin SM & Mundy GR. Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. Journal of Clinical Investigation 1988 82 680-685.
44. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K et al. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. Journal of Biological Chemistry 1998 273 27091-27096.
45. 2 in human bone marrow stroma cells. Biochemical and Biophysical Research Communications 1998 247 338-341.
46. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. Journal of Biological Chemistry 1997 272 25190-25194.
47. Anderson MA, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997 390 175-179.
48. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL & Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulate osteoprotegerin ligand mRNA levels in human osteoblastic cells. Bone 1999 24 (In Press).
49. O'Brien CA, Farrar NC & Manolagas SC. Identification of an OSF-2 binding site in the murine RANKL/OPGL gene promoter: a potential link between osteoblastogenesis and osteoclastogenesis. Bone 1998 23 (Suppl 1) S149 (Abstract no. 1003).
50. Gao Y-H, Shinki T, Yuase T, Kataoka-Enomoto H, Komori T, Suda T et al. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: Regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochemical and Biophysical Research Communications 1998 252 697-702.
51. Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 315-323.
52. Quinn JMW, Elliott J, Gillespie MT & Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998 139 4424-4427.
53. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochemical and Biophysical Research Communications 1998 246 199-204.
54. Udagawa N, Takahashi N, Matsuzaki K, Jimi E, Tsurukai T, Itoh K et al. Osteoblasts/stromal cells activate osteoclast function through osteoclast differentiation factor (ODF). Bone 1998 23 (Suppl 1) S220 (Abstract no. T072).
55. Jimi E, Akiyama S, Tsurukai T, Kobayashi K, Takahashi N, Udagawa N et al. Osteoclast differentiation factor (ODF) induces fusion, survival and activation of osteoclasts. Bone 1998 23 (Suppl 1) S222 (Abstract no. T079).
56. Wong BR, Josien R, Young Lee S, Sauter B, Li H-L, Steinman RM et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. Journal of Experimental Medicine 1997 186 2075-2080.
57. Darnay BG, Haridas V, Ni J, Moore PA & Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Journal of Biological Chemistry 1998 273 20551-20555.
58. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the USA 1999 96 3540-3545.
59. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochemical and Biophysical Research Communications 1998 253 395-400.
60. Wong BR, Josien R, Young Lee S, Vologodskaia M, Steinman RM & Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. Journal of Biological Chemistry 1998 273 28355-28359.
61. Arch RH, Gedrich RW & Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes and Development 1998 12 2821-2830.
62. Galibert L, Tometsko ME, Anderson DM, Cosman D & Dougall WC. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanism of receptor activator of NF-κB, a member of the TNFR superfamily. Journal of Biological Chemistry 1998 273 34120-34127.
63. Dadgostar H & Cheng G. An intact zinc finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-κB activation but is dispensible for c-Jun N-terminal kinase signaling. Journal of Biological Chemistry 1998 273 24775-24780.
64. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV & Baldwin AS. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998 281 1680-1683.
65. Lomaga MA, Yeh W-C, Sarosi I, Duncan GS, Furlonger C, Ho A et al. TRAF6-deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling. Genes and Development 1999 13 1015-1024.
66. Hing L, Carlson L, Siebenlist U & Boyce BF. Mechanisms by which NF-κB regulates osteoclast numbers. Bone 1998 23 (Suppl 1) S190 (Abstract no. 1172).
67. Riggs BL, Khosla S & Melton LJ. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. Journal of Bone and Mineral Research 1998 13 763-773.
68. Oursler MJ, Cortese C, Keeting PE, Anderson MA, Bonde SK, Riggs BL et al. Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology 1991 129 3313-3320.
69. Hughes DE, Dai A, Tiffee JC, Li HH & Mundy GR. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nature Medicine 1997 2 1132-1136.
70. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 1999 14 518-527.
71. Arrighi HM, Hsieh A, Wong H, Khoo H, Reyes A, Asbury D et al. Osteoprotegerin serum levels in healthy volunteers. Bone 1998 23 (Suppl 1) S298 (Abstract no. T411).
72. Sarma U, Edwards M, Motoyoshi K & Flanagan AM. Inhibition of bone resorption by 17β-estradiol in human bone marrow cultures. Journal of Cellular Physiology 1998 175 99-108.
73. Kimble RB, Srivastava S, Ross FP, Matayoshi A & Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1- and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. Journal of Biological Chemistry 1996 46 28890-28897.
74. Lukert B & Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Annals of Internal Medicine 1990 112 352-364.
75. Reid IR. Glucocorticoid osteoporosis - mechanisms and management. European Journal of Endocrinology 1997 137 209-217.
76. Delany AM, Dong Y & Canalis E. Mechanisms of glucocorticoid action in bone cells. Journal of Cellular Biochemistry 1994 56 295-302.
77. Canalis E. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. Journal of Clinical Endocrinology and Metabolism 1996 81 3441-3447.
78. Conaway HH, Grogorie D & Lerner UH. Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone. Journal of Bone and Mineral Research 1996 11 1419-1429.
79. 2. Journal of Bone and Mineral Research 1997 12 734-741.
80. Gronowicz G, McCarthy MB & Raisz LG. Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro. Journal of Bone and Mineral Research 1990 5 1223-1230.
81. Chiodini I, Carnevale V, Torlontano M, Fusilli S, Gugglielmi G, Pileri M et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 1863-1867.
82. Riggs BL, Jowsey J & Kelly PJ. Quantitative microradiographic study of bone remodeling in Cushing's syndrome. Metabolism 1966 15 773-780.
83. Dempster D. Bone histomorphometry in glucocorticoid-induced osteoporosis. Journal of Bone and Mineral Research 1998 13 137-141.
84. Felix R, Hofstetter W & Cecchini MG. Recent developments on the understanding of the pathophysiology of osteopetrosis. European Journal of Endocrinology 1996 134 143-156.
85. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A & Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Medicine 1998 3 1285-1289.
86. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990 345 442-444.
87. Horwood NJ, Kartsgiannis V, Lam MHC, Romas E, Quinn JMW, Martin TJ et al. Activated T cells are capable of inducing osteoclast formation: a mechanism for rheumatoid arthritis. Bone 1998 23 (Suppl 1) S214 (Abstract no. T046).
88. Kotake S, Udagawa N, Takahashi N, Yano K, Tsuda E, Higashio K et al. Presence of osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluids from patients with rheumatoid arthritis. Arthritis and Rheumatism 1998 41 (Suppl) S320 (Abstract no. 1727).